Pasage: patient supported approaches to gene editing
Ended Project Grant Awarded Last action
- Award ID
- R01HG011461
- Recipient
-
Mayo Clinic Jacksonville (A Nonprofit Corporation) UEI GKPBCFV1QMM3 Part of Mayo Clinic
- Awarding agency
-
National Human Genome Research Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,430,921
Award facts
- Assistance listing
- 93.172 Human Genome Research
- Completion date
- Place of performance
- Florida, USA
Award details come from USAspending.gov.
Description
- Abstract
- The development of new methods for prenatal genetic editing in humans has accelerated the translation of technologies designed to disrupt disease mechanisms or remove disease-causing mutations entirely. These technologies show promise for preemptively addressing previously intractable genetic conditions. However, recent events have demonstrated considerable gaps in the governance structure surrounding human gene editing and its translation to clinical practice. Since the discovery that a scientist in china had conducted human experiments allegedly resulting in the birth of three genetically edited children, numerous calls have been made for a novel governance structure for prenatal human gene editing, frequently framed around moratoria or other forms of suppression, and several international bodies have convened. There has been strong pressure towards a values-based governance approach that moves beyond traditional technocratic considerations of safety and efficacy and takes into account collective normative deliberation about the ethics of prenatal intervention. This is challenging in the united states context, which is among the few high-income countries without centralized regulation of research on embryos and/or translational assisted reproductive technologies. As such, two important stakeholder voices have been largely left out of conversations around the future of prenatal gene editing in the US context: the patients and families that might be benefitted or harmed by the translation of prenatal gene editing and the scientists and clinicians who would be on the front lines of clinical translation were IT to move forward. We propose to fill this GAP by conducting empirical research with these key stakeholders that assesses potential governance approaches internationally and explores how they may be implemented in an united states context. The goal is to move past generalizations to explore the direct policy mechanisms that are feasible while incorporating the values and priorities of end users. This study consists of three aims. The first two, contemporaneous, aims will consist of qualitative research with two sets of stakeholders: patients and families affected by genetic conditions potentially addressable through prenatal gene editing and clinicians and scientists involved in relevant translational and clinical activities in this space. In aim 1, we will begin by conducting a review of the international science policy landscape to gather policy mechanisms that have been proposed or implemented to manage emerging technologies in the reproductive science, genetics, and regenerative medicine spaces. We will identify policies that fall into a spectrum from permissive to restrictive. These policies will be shared with stakeholders during qualitative interviews to assess their concordance with stakeholder values and priorities. We will recruit a diverse cohort of clinicians and scientist leaders from 20 key professional societies and conduct qualitative interview to assess underlying normative underpinnings of proposed policy approaches, professional feasibility of proposals, and values and priorities around the potential translation of prenatal gene editing in humans. The results of this aim will feed directly into the deliberative democracy exercises in aim 3. In aim 2, we will partner with genetic alliance, the largest patient advocacy organization for genetic conditions to recruit a panel of patient advisors from communities affected by 9 genetic conditions from across a spectrum of penetrance and severity. Together with the advisors we will connect with patient advocacy and support groups in these communities to recruit a cohort of patients and family members. Patients will be asked to share their understanding of the potential of gene editing, their aspirations or concerns about its clinical applications, their priorities and goals in researc
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$403,379 | |
| Amendment | $0 | |
| Amendment | $210,041 | |
| Amendment | $210,041 | |
| Amendment | $809,447 | |
| Amendment | $809,447 | |
| Amendment | $637,291 | |
| Amendment | $637,291 | |
| Amendment | $760,371 | |
| Original award | $760,371 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Miami | $269,556 | |
| Case Western Reserve University | $345,008 | |
| Eidg. Technische Hochschule (Ethz) | $42,607 | |
| ST Michael's Hospital | $9,180 |
Quick answers
Who received award R01HG011461?
R01HG011461 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Human Genome Research Institute (National Institutes of Health) on September 23, 2022.
How much is award R01HG011461 worth?
$4,430,921 has been obligated on R01HG011461.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award